Cost-effectiveness analysis of two therapeutic schemes in the treatment of acromegaly: a retrospective study of 168 cases

J Endocrinol Invest. 2015 Jul;38(7):717-23. doi: 10.1007/s40618-015-0242-6. Epub 2015 Mar 18.

Abstract

Purpose: This study aimed to estimate the cost effectiveness of two therapeutic schemes, including preoperative medical therapy and surgery as primary therapy.

Methods: A total of 168 acromegaly cases were retrospectively investigated for a comparative evaluation of surgery and preoperative medical therapy. A Markov model was developed to simulate treatment cost-effectiveness and progression of acromegaly.

Results: Overall effectiveness of preoperative medical therapy was significantly higher than surgery in acromegalic patients with macroadenoma. In addition, life expectancy, and cost per life-year gained were slightly higher in the preoperative medical therapy group than in the initial surgery group when patients received surgery as a secondary treatment. Interestingly, preoperative medical therapy achieved a significant increase in life expectancy and reduced cost for patients who received long-term medical therapy as secondary treatment.

Conclusions: In acromegalic patients with macroadenoma, the cost-effectiveness analysis revealed more satisfactory outcomes in preoperative therapy, compared with primary surgery.

Keywords: Acromegaly; Cancer therapy; Cost-effectiveness analysis; Macroadenoma; Markov model; Retrospective analysis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acromegaly / drug therapy
  • Acromegaly / economics
  • Acromegaly / surgery
  • Adenoma* / drug therapy
  • Adenoma* / economics
  • Adenoma* / surgery
  • Adult
  • Aged
  • Cost-Benefit Analysis*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Outcome Assessment, Health Care* / economics
  • Pituitary Neoplasms* / drug therapy
  • Pituitary Neoplasms* / economics
  • Pituitary Neoplasms* / surgery
  • Retrospective Studies